Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Antibodies to intracellular cancer antigens combined with chemotherapy enhance anti-cancer immunity

14.02.2012
Pre-clinical study shows delay in tumor growth and prolonged survival time

An international team of scientists in Japan, Switzerland, and the United States has confirmed that combining chemotherapy and immunotherapy in cancer treatment enhances the immune system's ability to find and eliminate cancer cells, even when the cancer-associated proteins targeted by the immune system are hidden behind the cancer cell membrane.

In a study published in Cancer Research by Noguchi et al., the scientists show that antibodies, which have been successful in treating certain types of cancers, can effectively reach elusive intracellular targets, delaying tumor growth and prolonging survival when combined with chemotherapy.

"The study provides proof-of-principle for a powerful new strategy that may greatly expand the arsenal of potential targets for cancer drug development and that could be broadly applicable to many different cancer types," said Hiroyoshi Nishikawa, M.D., Ph.D., a Cancer Research Institute (CRI)-funded associate professor in the Department of Experimental Immunology at the Immunology Frontier Research Center, Osaka University, and a senior author on the paper.

The introduction of antibodies against cancer represents one of the biggest successes of cancer therapy over the past 20 years. These treatments work by targeting markers on the surface of cancer cells, and include the blockbuster therapies Herceptin, which targets the HER2/neu marker on breast cancer cells, and Rituxan, which targets the CD20 marker on B cell lymphoma.

The majority of markers that can distinguish cancer cells from normal cells, however, are found exclusively inside cancer cells, where antibodies typically cannot access them. "Therapies that can successfully target cancer antigens found within cancer cells may be able to fight cancer without causing unwanted side effects due to collateral damage to healthy cells," said study co-lead author Gerd Ritter, Ph.D., associate director of the New York Branch of the Ludwig Institute for Cancer Research (LICR), and a leading member of the CRI/LICR Cancer Vaccine Collaborative, which also supported the study.

To assess whether antibody treatment against an intracellular antigen might be successful, the researchers used an antibody against the prototypic cancer antigen NY-ESO-1 and tested it in a model of colon cancer engineered to express NY-ESO-1 within its cancer cells. Alone, the antibody had no effect against the cancer. By using chemotherapy to release NY-ESO-1 from the cancer cells prior to the administration of the antibody, however, they were able to significantly delay cancer progression and prolong survival. The researchers then tested the strategy in another cancer model using a different type of chemotherapy and showed similar results, demonstrating that this approach could be applicable to different tumor types using various standard chemotherapies.

By monitoring the immune responses to these treatments, the researchers on the study found that the anti-tumor effect of the combination was dependent on CD8+, or killer, T cells. Rather than working to kill the cancer cells directly, the antibody worked by binding to the NY-ESO-1 antigen and facilitating its presentation to CD8+ T cells, which then exerted the anti-tumor effects. These findings not only have implications for how scientists understand the mechanisms of current antibody treatments for cancer, but they also shed light on a fundamental question in clinical cancer immunology, which asks how people develop spontaneous antibody and/or CD8+ T cell responses against NY-ESO-1.

"These studies are also representative of a growing trend in immunotherapy treatment, namely the use of chemotherapy and other standard therapies to augment anti-tumor immunity," stated Hiroshi Shiku, M.D., chairman and professor in the Department of Medical Oncology and Immunology, Mie University Graduate School of Medicine, Japan, and a lead investigator on the study. Until very recently, it was thought that these treatments served to uniformly dampen the immune system and would therefore limit the potential efficacy of immunotherapies used in tandem or in sequence. A growing body of literature, however, is suggesting that certain cytotoxic, or "cell-killing," therapies such as chemotherapy and radiation, used in strategic ways, can synergize with immunotherapies to strengthen or expand the anti-tumor immune response.

Based on the success of their preclinical investigations, the study researchers are eager to take the approach into clinical testing. Such a trial would bridge what immunologists refer to as passive immunotherapy and active immunotherapy.

"It's passive because we're using antibodies manufactured outside the body—the body doesn't have to do the work to make these antibodies; but it's also active because these antibodies then mobilize the immune system to actively begin producing potent cells and endogenous molecules like cytokines and complement to attack the tumor. It's a powerful strategy that for the first time capitalizes on the full therapeutic potential of antibodies as mediators of tumor elimination," Ritter said.

Publication Reference: Noguchi et al. Intracellular tumor-associated antigens represent effective targets for passive immunotherapy. Cancer Res. canres.3072.2011; Published OnlineFirst February 8, 2012;

About the Cancer Research Institute

The Cancer Research Institute, a nonprofit established in 1953, is the global leader in cancer immunology. Since its inception, CRI has invested hundreds of millions of dollars to support research conducted by more than 3,000 scientists and clinicians worldwide to understand the immune system and how it can be harnessed to conquer all cancers. This work has laid the foundation for nearly every major cancer immunotherapy breakthrough over the past half century. Guided by an international panel of the world's leading immunologists and cancer immunologists, including three Nobel laureates and 29 members of the U.S. National Academy of Sciences, CRI provides essential funding to support every stage of discovery, from laboratory investigation to clinical trials of the most promising cancer immunotherapies for patients. CRI also sponsors a seminal international symposium on cancer immunology each year, hosts annual colloquia dedicated to overcoming challenges in immunotherapy research and development, forges collaborative partnerships between academia and industry to facilitate the development pathway for novel immunotherapeutics, and presents special recognition awards to individuals who have made outstanding contributions to cancer research, patient care, and public awareness. Through its sustaining support and leadership in the field, CRI is accelerating the development of better, safer, and more effective immunotherapies that stand to revolutionize the treatment of all cancers. For more information, visit http://cancerresearch.org.
About The Ludwig Institute for Cancer Research

LICR is an international non-profit organization committed to improving the understanding and control of cancer through integrated laboratory and clinical discovery. Leveraging its worldwide network of investigators and the ability to sponsor and conduct its own clinical trials, the Institute is actively engaged in translating its discoveries into applications for patient benefit. Since its establishment in 1971, the Institute has expended more than $1.5 billion on cancer research.
About the Cancer Vaccine Collaborative

The Cancer Vaccine Collaborative (CVC), a joint program of the Cancer Research Institute (CRI) and the Ludwig Institute for Cancer Research Ltd (LICR), is a coordinated global network of clinical trial sites, with special expertise in immunology, conducting parallel early stage clinical trials to identify the optimal composition of successful therapeutic cancer vaccines. CVC investigators are supported by a comprehensive independent trials management infrastructure that provides regulatory, safety, and compliance expertise and oversight, trial management, shared data collection software, intellectual property management, and funding. Since the program's inception in 2001, the Collaborative has completed or is currently conducting more than 45 early phase clinical trials of therapeutic cancer vaccines. For more information, go to http://www.cancerresearch.org/collaborative.

Rachel Steinhardt | EurekAlert!
Further information:
http://www.licr.org

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>